Cardiovascular Systems (CSII) Raised to “Hold” at BidaskClub

Cardiovascular Systems (NASDAQ:CSII) was upgraded by equities researchers at BidaskClub from a “sell” rating to a “hold” rating in a note issued to investors on Monday.

A number of other analysts have also issued reports on the company. William Blair reaffirmed a “market perform” rating on shares of Cardiovascular Systems in a research report on Thursday, December 21st. Needham & Company LLC lowered Cardiovascular Systems from a “buy” rating to a “hold” rating and dropped their target price for the stock from $33.11 to $23.00 in a research report on Friday, December 15th. Zacks Investment Research lowered Cardiovascular Systems from a “buy” rating to a “hold” rating in a research report on Monday, February 12th. Leerink Swann dropped their target price on Cardiovascular Systems from $31.00 to $30.00 and set an “outperform” rating on the stock in a research report on Thursday, February 8th. Finally, ValuEngine lowered Cardiovascular Systems from a “hold” rating to a “sell” rating in a research report on Friday, February 2nd. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and one has given a buy rating to the company. Cardiovascular Systems has an average rating of “Hold” and a consensus price target of $27.00.

How to Become a New Pot Stock Millionaire

NASDAQ:CSII opened at $22.87 on Monday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 4.13 and a current ratio of 4.65. Cardiovascular Systems has a 12 month low of $20.58 and a 12 month high of $33.11. The stock has a market capitalization of $759.70, a price-to-earnings ratio of 762.33 and a beta of 2.15.

Cardiovascular Systems (NASDAQ:CSII) last released its quarterly earnings data on Wednesday, February 7th. The medical device company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.04) by $0.03. Cardiovascular Systems had a negative return on equity of 0.50% and a negative net margin of 1.62%. The company had revenue of $52.63 million for the quarter, compared to analyst estimates of $53.39 million. During the same period last year, the company posted $0.03 earnings per share. The firm’s revenue was up 5.2% compared to the same quarter last year. equities research analysts anticipate that Cardiovascular Systems will post -0.07 EPS for the current fiscal year.

A number of large investors have recently bought and sold shares of CSII. Teacher Retirement System of Texas acquired a new position in Cardiovascular Systems in the fourth quarter worth about $273,000. US Bancorp DE grew its stake in Cardiovascular Systems by 51.7% in the fourth quarter. US Bancorp DE now owns 13,208 shares of the medical device company’s stock worth $313,000 after purchasing an additional 4,500 shares in the last quarter. MetLife Investment Advisors LLC acquired a new position in Cardiovascular Systems in the fourth quarter worth about $354,000. Capital Fund Management S.A. grew its stake in Cardiovascular Systems by 54.5% in the fourth quarter. Capital Fund Management S.A. now owns 27,500 shares of the medical device company’s stock worth $651,000 after purchasing an additional 9,700 shares in the last quarter. Finally, Acadian Asset Management LLC acquired a new position in Cardiovascular Systems in the fourth quarter worth about $756,000. Institutional investors and hedge funds own 82.55% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Cardiovascular Systems (CSII) Raised to “Hold” at BidaskClub” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/09/cardiovascular-systems-csii-raised-to-hold-at-bidaskclub.html.

About Cardiovascular Systems

Cardiovascular Systems, Inc is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications.

Analyst Recommendations for Cardiovascular Systems (NASDAQ:CSII)

Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply